Published in Cancer Cell on March 16, 2010
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol (2006) 10.39
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35
Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer (2008) 4.25
Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol (2011) 3.52
Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene (2004) 3.27
The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res (2003) 3.18
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol (2007) 2.85
Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem (2003) 2.77
The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol (2007) 2.74
A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J (2002) 2.42
Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys (2004) 2.41
p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. EMBO J (2006) 2.23
LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J (2004) 2.20
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J (2002) 2.17
EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors. Sci Signal (2010) 2.16
Hsp90 recognizes a common surface on client kinases. J Biol Chem (2006) 2.12
Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A (2005) 2.00
Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta (2007) 1.97
Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell (2011) 1.89
Tal, a Tsg101-specific E3 ubiquitin ligase, regulates receptor endocytosis and retrovirus budding. Genes Dev (2004) 1.73
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A (2009) 1.71
The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle (2004) 1.54
Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Curr Biol (2003) 1.50
Roles for growth factors in cancer progression. Physiology (Bethesda) (2010) 1.48
Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep (2004) 1.46
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A (2010) 1.46
Src promotes destruction of c-Cbl: implications for oncogenic synergy between Src and growth factor receptors. Proc Natl Acad Sci U S A (2003) 1.44
Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. J Biol Chem (2006) 1.42
Endocytosis and cancer. Cold Spring Harb Perspect Biol (2013) 1.40
Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett (2010) 1.30
Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem (2004) 1.30
An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase controlling EGFR endocytosis. Curr Biol (2009) 1.30
Systems biology of growth factor-induced receptor endocytosis. Traffic (2008) 1.26
Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol (2007) 1.25
ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture. Endocrinology (2002) 1.19
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci U S A (2007) 1.18
EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J (2011) 1.17
miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Mol Med (2012) 1.14
Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem (2004) 1.14
Coupled pre-mRNA and mRNA dynamics unveil operational strategies underlying transcriptional responses to stimuli. Mol Syst Biol (2011) 1.13
Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol (2004) 1.11
Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7. Dev Cell (2003) 1.07
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett (2005) 1.06
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci U S A (2013) 1.06
Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci U S A (2013) 1.05
ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy. Int J Cancer (2006) 1.05
Genomic amplicons target vesicle recycling in breast cancer. J Clin Invest (2009) 1.04
Regulation of signalling by microRNAs. Biochem Soc Trans (2012) 1.02
The role of ubiquitylation in signaling by growth factors: implications to cancer. Semin Cancer Biol (2003) 1.01
Kinase-mediated quasi-dimers of EGFR. FASEB J (2010) 1.01
c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene (2003) 1.00
Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res (2005) 0.98
The locus of microRNA-10b: a critical target for breast cancer insurgence and dissemination. Cell Cycle (2013) 0.96
Hsp90 increases LIM kinase activity by promoting its homo-dimerization. FASEB J (2006) 0.96
Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol Oncol (2007) 0.95
Monoubiquitylation: a recurrent theme in membrane protein transport. Isr Med Assoc J (2006) 0.95
Context-specific microRNA analysis: identification of functional microRNAs and their mRNA targets. Nucleic Acids Res (2012) 0.92
Signal transduction: molecular ticket to enter cells. Nature (2002) 0.92
Consistency test of the cell cycle: roles for p53 and EGR1. Cancer Res (2012) 0.90
Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling. J Biol Chem (2006) 0.90
Phosphorylation of carboxyl-terminal tyrosines modulates the specificity of Sprouty-2 inhibition of different signaling pathways. J Biol Chem (2005) 0.89
Monoubiquitinylation regulates endosomal localization of Lst2, a negative regulator of EGF receptor signaling. Dev Cell (2009) 0.86
Beta-catenin/HuR post-transcriptional machinery governs cancer stem cell features in response to hypoxia. PLoS One (2013) 0.84
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Crit Rev Oncol Hematol (2010) 0.83
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2. Proc Natl Acad Sci U S A (2013) 0.82
Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance. Transl Oncol (2011) 0.82
Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands. Proc Natl Acad Sci U S A (2010) 0.82
ERK-ERF-EGR1, a novel switch underlying acquisition of a motile phenotype. Cell Adh Migr (2012) 0.81
Epidermal growth-factor-induced transcript isoform variation drives mammary cell migration. PLoS One (2013) 0.80
MAP Kinase activation by receptor tyrosine kinases: in control of cell migration. Methods Mol Biol (2010) 0.80
A crossroad of microRNAs and immediate early genes (IEGs) encoding oncogenic transcription factors in breast cancer. J Mammary Gland Biol Neoplasia (2012) 0.79
qCMA: a desktop application for quantitative collective cell migration analysis. J Biomol Screen (2012) 0.79
Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: results of in vitro and in vivo studies. Head Neck (2012) 0.78
Enlightened receptor dynamics. Nat Biotechnol (2004) 0.77
EGF receptor family: twisting targets for improved cancer therapies. Growth Factors (2014) 0.77
Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies. Int Immunol (2011) 0.77
In vitro and in vivo assays of monoubiquitination of receptor tyrosine kinases. Methods Mol Biol (2006) 0.77
ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy. Prostate (2007) 0.75
Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy. Methods Mol Biol (2015) 0.75
Signaling by growth factor receptors. Methods Mol Biol (2004) 0.75
The International Consortium on Systems Biology of Receptor Tyrosine Kinase Regulatory Networks. Syst Biol (Stevenage) (2005) 0.75